Amorfix Life Sciences and CNJ Holdings have signed an agreement to identify and develop therapeutic antibodies targeting disease specific epitopes (DSEs). 

The collaboration will make use of Amorfix's ProMIS discovery technology and the terms of the deal are kept confidential.

Amorfix president and CEO Dr. Robert Gundel said, "This collaboration represents the ideal situation where two companies come together with complementary expertise, resources and technology in a united effort to identify and develop novel antibody therapeutics for the treatment of cancer."

The collaboration is expected to expand Amorfix cancer therapeutic pipeline of antibodies directed against misfolded protein targets.

Cangene president and CEO John Sedor said, "This is an opportunity to leverage our core competencies to accelerate the development of therapeutic antibodies to novel targets in the oncology space."